Modafinil and Armodafinil for ADHD Treatment

Current Recommended Pharmacological Treatments for ADHD

The American Academy of Pediatrics recommends stimulants, such as methylphenidate and amphetamines, as first-line pharmacological treatment for elementary school-aged children (6-11 years) with strong evidence 1, 2
The American Academy of Pediatrics suggests non-stimulant medications, including atomoxetine, extended-release guanfacine, and extended-release clonidine, with sufficient but less strong evidence for elementary school-aged children (6-11 years) 1, 2
For preschool-aged children (4-5 years), the American Academy of Pediatrics recommends methylphenidate if behavioral interventions are insufficient and there is moderate-to-severe functional impairment 1, 3

The treatment algorithm recommends stimulant medications, such as methylphenidate and amphetamines, as first-line pharmacotherapy 4
If stimulant medications are ineffective or not tolerated, switching to an alternative stimulant class is recommended 2
If stimulants are contraindicated or ineffective, non-stimulants, such as atomoxetine, extended-release guanfacine, and extended-release clonidine, should be considered 2, 5

There is insufficient evidence supporting the use of armodafinil for ADHD treatment, according to the American Academy of Pediatrics 1, 2, 4

Clinicians should follow established treatment guidelines that recommend stimulants, such as methylphenidate and amphetamines, as first-line pharmacotherapy, followed by non-stimulants, such as atomoxetine, extended-release guanfacine, and extended-release clonidine, due to the availability of multiple FDA-approved medications with stronger evidence of efficacy and safety 1, 2, 4